Shaun Sabico1, Mushira A Enani2, Eman Sheshah3, Naji J Aljohani1,4, Dara A Aldisi5, Naif H Alotaibi6, Naemah Alshingetti7, Suliman Y Alomar8, Abdullah M Alnaami1, Osama E Amer1, Syed D Hussain1, Nasser M Al-Daghri1. 1. Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh 11451, Saudi Arabia. 2. Infectious Diseases Section, King Fahad Medical City, Riyadh 59046, Saudi Arabia. 3. Diabetes Care Center, King Salman Bin Abdulaziz Hospital, Riyadh 12769, Saudi Arabia. 4. Obesity, Endocrine and Metabolism Center, Department of Medicine, King Fahad Medical City, Riyadh 59046, Saudi Arabia. 5. Department of Community Health Sciences, College of Applied Medical Sciences, King Saud University, Riyadh 11451, Saudi Arabia. 6. Department of Medicine, College of Medicine, King Saud University, Riyadh 12372, Saudi Arabia. 7. Obstetrics and Gynaecology Department, King Salman Bin Abdulaziz Hospital, Riyadh 11564, Saudi Arabia. 8. Doping Research Chair, Department of Zoology, College of Science, King Saud University, Riyadh 11495, Saudi Arabia.
Abstract
OBJECTIVE: Vitamin D deficiency has been associated with an increased risk of COVID-19 severity. This multi-center randomized clinical trial aims to determine the effects of 5000 IU versus 1000 IU daily oral vitamin D3 supplementation in the recovery of symptoms and other clinical parameters among mild to moderate COVID-19 patients with sub-optimal vitamin D status. STUDY DESIGN AND SETTING: A total of 69 reverse transcriptase polymerase chain reaction (RT-PCR) SARS-CoV-2 positive adults who were hospitalized for mild to moderate COVID-19 disease were allocated to receive once daily for 2 weeks either 5000 IU oral vitamin D3 (n = 36, 21 males; 15 females) or 1000IU oral vitamin D3 (standard control) (n = 33, 13 males; 20 females). Anthropometrics were measured and blood samples were taken pre- and post-supplementation. Fasting blood glucose, lipids, serum 25(OH)D, and inflammatory markers were measured. COVID-19 symptoms were noted on admission and monitored until full recovery. RESULTS:Vitamin D supplementation for 2 weeks caused a significant increase in serum 25(OH)D levels in the 5000 IU group only (adjusted p = 0.003). Within-group comparisons also showed a significant decrease in BMI and IL-6 levels overtime in both groups (p-values < 0.05) but was not clinically significant in between-group comparisons. Kaplan-Meier survival analysis revealed that the 5000 IU group had a significantly shorter time to recovery (days) than the 1000 IU group in resolving cough, even after adjusting for age, sex, baseline BMI, and D-dimer (6.2 ± 0.8 versus 9.1 ± 0.8; p = 0.039), and ageusia (loss of taste) (11.4 ± 1.0 versus 16.9 ± 1.7; p = 0.035). CONCLUSION: A 5000 IU daily oral vitamin D3 supplementation for 2 weeks reduces the time to recovery for cough and gustatory sensory loss among patients with sub-optimal vitamin D status and mild to moderate COVID-19 symptoms. The use of 5000 IU vitamin D3 as an adjuvant therapy for COVID-19 patients with suboptimal vitamin D status, even for a short duration, is recommended.
RCT Entities:
OBJECTIVE:Vitamin Ddeficiency has been associated with an increased risk of COVID-19 severity. This multi-center randomized clinical trial aims to determine the effects of 5000 IU versus 1000 IU daily oral vitamin D3 supplementation in the recovery of symptoms and other clinical parameters among mild to moderate COVID-19patients with sub-optimal vitamin D status. STUDY DESIGN AND SETTING: A total of 69 reverse transcriptase polymerase chain reaction (RT-PCR) SARS-CoV-2 positive adults who were hospitalized for mild to moderate COVID-19 disease were allocated to receive once daily for 2 weeks either 5000 IU oral vitamin D3 (n = 36, 21 males; 15 females) or 1000 IU oral vitamin D3 (standard control) (n = 33, 13 males; 20 females). Anthropometrics were measured and blood samples were taken pre- and post-supplementation. Fasting blood glucose, lipids, serum 25(OH)D, and inflammatory markers were measured. COVID-19 symptoms were noted on admission and monitored until full recovery. RESULTS:Vitamin D supplementation for 2 weeks caused a significant increase in serum 25(OH)D levels in the 5000 IU group only (adjusted p = 0.003). Within-group comparisons also showed a significant decrease in BMI and IL-6 levels overtime in both groups (p-values < 0.05) but was not clinically significant in between-group comparisons. Kaplan-Meier survival analysis revealed that the 5000 IU group had a significantly shorter time to recovery (days) than the 1000 IU group in resolving cough, even after adjusting for age, sex, baseline BMI, and D-dimer (6.2 ± 0.8 versus 9.1 ± 0.8; p = 0.039), and ageusia (loss of taste) (11.4 ± 1.0 versus 16.9 ± 1.7; p = 0.035). CONCLUSION: A 5000 IU daily oral vitamin D3 supplementation for 2 weeks reduces the time to recovery for cough and gustatory sensory loss among patients with sub-optimal vitamin D status and mild to moderate COVID-19 symptoms. The use of 5000 IU vitamin D3 as an adjuvant therapy for COVID-19patients with suboptimal vitamin D status, even for a short duration, is recommended.
Entities:
Keywords:
COVID-19; clinical trial; saudi; vitamin D; vitamin D insufficiency
Authors: Goran Bjelakovic; Lise Lotte Gluud; Dimitrinka Nikolova; Kate Whitfield; Jørn Wetterslev; Rosa G Simonetti; Marija Bjelakovic; Christian Gluud Journal: Cochrane Database Syst Rev Date: 2014-01-10
Authors: Yousef Al Saleh; Salem A Beshyah; Wiam Hussein; Abdulrazzaq Almadani; Ahmed Hassoun; Ali Al Mamari; Ebtesam Ba-Essa; Essa Al-Dhafiri; Mohammed Hassanein; Mona A Fouda; Nadia Al Ali; Naji Aljohani; Nasreen Al-Sayed; Neil Gittoes; Tarik Elhadd; Waleed Al-Baker; Shaun Sabico; Nasser Al-Daghri Journal: Arch Osteoporos Date: 2020-03-02 Impact factor: 2.617
Authors: Daniel Wrapp; Nianshuang Wang; Kizzmekia S Corbett; Jory A Goldsmith; Ching-Lin Hsieh; Olubukola Abiona; Barney S Graham; Jason S McLellan Journal: Science Date: 2020-02-19 Impact factor: 47.728
Authors: Yi Xu; David J Baylink; Chien-Shing Chen; Mark E Reeves; Jeffrey Xiao; Curtis Lacy; Eric Lau; Huynh Cao Journal: J Transl Med Date: 2020-08-26 Impact factor: 5.531
Authors: Tatiana L Karonova; Ksenia A Golovatyuk; Igor V Kudryavtsev; Alena T Chernikova; Arina A Mikhaylova; Arthur D Aquino; Daria I Lagutina; Ekaterina K Zaikova; Olga V Kalinina; Alexey S Golovkin; William B Grant; Evgeny V Shlyakhto Journal: Nutrients Date: 2022-06-23 Impact factor: 6.706
Authors: Miguel Cervero; Daniel López-Wolf; Guiomar Casado; Maria Novella-Mena; Pablo Ryan-Murua; María Luisa Taboada-Martínez; Sara Rodríguez-Mora; Lorena Vigón; Mayte Coiras; Montserrat Torres Journal: Front Pharmacol Date: 2022-07-04 Impact factor: 5.988
Authors: Javier S Morales; Pedro L Valenzuela; Adrián Castillo-García; Javier Butragueño; David Jiménez-Pavón; Pedro Carrera-Bastos; Alejandro Lucia Journal: Nutrients Date: 2021-12-22 Impact factor: 5.717
Authors: Ahmed S Mohammed Metwally; Sobhy M Yakout; Malak N K Khattak; Ghadah Alkhaldi; Nasser M Al-Daghri Journal: Int J Environ Res Public Health Date: 2021-12-10 Impact factor: 3.390